文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

Cardioband系统经导管二尖瓣修复功能性二尖瓣反流:1年结果

Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes.
PubMed 文献 · Eur Heart J · 2019-01-01

这项多中心研究纳入60例中重度继发性二尖瓣反流患者,在指南推荐药物治疗基础上接受Cardioband经导管二尖瓣环成形术。1年时61%患者MR程度为中度及以下,功能状态与生活质量显著改善,但锚定脱位导致部分器械失效,研究中期进行了器械改良。

要点

  • Cardioband术后1年61%患者MR≤中度,功能与生活质量显著改善
  • 锚定脱位见于10例,多发生在前半组患者,促使器械改良
  • 1年总体生存87%,免于心衰再入院生存66%,免于再干预生存78%

核心结论

  • Cardioband二尖瓣系统在多中心试验中表现出合理的性能和安全性,1年时多数患者MR≤中度且功能显著改善。

研究设计与样本

  • 多中心前瞻性研究,2013至2016年间11家欧洲中心连续纳入60例中重度继发性二尖瓣反流患者,年龄72±7岁,60%为缺血性病因,均在接受指南推荐药物治疗。

主要发现

  • 院内死亡2例(均非器械相关),卒中1例,冠状动脉并发症2例,心包填塞1例。
  • 锚定脱位10例(除1例外均发生在前半组患者),导致5例器械失效,研究中期器械改良以减轻该问题。
  • 技术成功97%(58/60),器械成功72%(43/60),手术成功68%(41/60)(按MVARC标准)。
  • 1年总体生存87%,免于心衰再入院生存66%,免于再干预生存78%(7例接受再干预)。
  • 12个月时总体人群MR≤中度61%;1年时接受经胸超声心动图的39例中MR≤中度95%,但11例(22%)MR加重至少一个等级。

临床怎么用

  • 对于指南推荐药物治疗下仍有中重度继发性二尖瓣反流的患者,Cardioband可作为经导管修复选择之一,需关注锚定脱位风险及术后MR加重可能。

局限性

  • 单臂研究,无对照组,样本量较小(60例),1年超声心动图随访仅39例,锚定脱位问题在早期病例中更突出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The Cardioband™ (Edwards Lifesciences) is a transcatheter implant designed to reduce mitral annulus size and mitral regurgitation (MR) severity. We report the 1-year outcomes of consecutive patients who underwent the Cardioband procedure between 2013 and 2016. METHODS AND RESULTS: Sixty patients with moderate or severe secondary MR (72 ± 7 years, 60% ischaemic origin) on guideline-recommended medical therapy were treated and analyzed at 11 European institutions. There were two in-hospital deaths (none device-related), one stroke, two coronary artery complications, and one tamponade. Anchor disengagement, observed in 10 patients (all but one in the first half of the population), resulted in device inefficacy in five patients and led to device modification half way through the study to mitigate this issue. Technical, device, and procedural successes, assessed based on Mitral Valve Academic Research Consortium (MVARC) criteria, were 97% (58/60), 72% (43/60), and 68% (41/60), respectively. At 1-year, overall survival, survival free of readmission for heart failure, and survival free of reintervention (performed in seven patients) were 87%, 66%, and 78%, respectively. In the overall population, MR grade at 12 months was moderate or less 61% and moderate or less in 95% of the 39 patients who underwent a transthoracic echocardiography at 1-year [but worsened by at least one grade in 11 patients (22%)]. Functional status (79% vs. 14% in New York Heart Association Class I/II), quality of life (-19 points on the Minnesota Living with Heart Failure Questionnaire score), and exercise capacity (+58 m by 6MWT) improved significantly (all P < 0.01). CONCLUSION: In this multicentre trial, the Cardioband mitral system demonstrated reasonable performance and safety. At 1 year, most patients had moderate or less MR and experienced significant functional improvements. A randomized controlled trial is underway to demonstrate the impact of Cardioband in patients on guideline-directed medical therapy.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Messika-Zeitoun D, Nickenig G, Latib A, et al. Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes. Eur Heart J. 2019. PMID: 30124798. doi:10.1093/eurheartj/ehy424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。